Related Experiment Video

Updated: Oct 12, 2026

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

Inhibition of human leucocytes locomotion by anti-inflammatory drugs

S Spisani, G Vanzini, S Traniello

    Experientia
    |June 15, 1979
    PubMed

    Insights

    Acidic non-steroidal anti-inflammatory drugs (NSAIDs) were found to inhibit human neutrophil (PMN) movement in laboratory tests. Further research is needed to understand the exact way these common drugs affect cell function.

    Area of Science:

    • Pharmacology
    • Immunology
    • Cell Biology

    Background:

    • Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation relief.
    • Neutrophils play a critical role in the inflammatory response.
    • The effects of NSAIDs on neutrophil function are not fully understood.

    Purpose of the Study:

    • To investigate the effect of acidic NSAIDs on human neutrophil locomotion in vitro.
    • To propose a potential mechanism of action for NSAID-induced inhibition of neutrophil movement.

    Main Methods:

    • Human neutrophils (PMNs) were isolated.
    • Cell locomotion was assessed in vitro in the presence of varying concentrations of acidic NSAIDs.

    Main Results:

    • Low concentrations of acidic NSAIDs significantly inhibited human PMN locomotion.
    • The inhibitory effect was observed in vitro.

    Conclusions:

    • Acidic NSAIDs can impair neutrophil motility.
    • A speculative mechanism for this observed inhibition is proposed, warranting further investigation.

    More Related Videos

    A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs04:15

    A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs

    Published on: February 2, 2024

    In Vivo Imaging Uncovers the Migratory Behavior of Leukocytes within the Joints10:10

    In Vivo Imaging Uncovers the Migratory Behavior of Leukocytes within the Joints

    Published on: December 9, 2025

    Related Concept Videos

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
    Antiasthma Drugs: Leukotriene Modifiers01:19

    Antiasthma Drugs: Leukotriene Modifiers

    Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
    Leukotriene modifiers work through two distinct mechanisms:
    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

    Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

    Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
    Antiprotozoal Agents01:21

    Antiprotozoal Agents

    Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...